MINIMALLY INVASIVE SPINE PROCEDURES · GUIDE 02 OF 04
Vertiflex® Procedure
Superion® Indirect Decompression System (Interspinous Spacer) Stand-alone interspinous process decompression for moderate lumbar spinal stenosis
A comprehensive operational reference on clinical appropriateness, patient selection, medical necessity, Medicare and commercial payer coverage, prior authorization workflow, coding fundamentals, device considerations, and denial prevention for the Vertiflex Procedure using the Superion Indirect Decompression System — an FDA premarket-approved interspinous spacer that indirectly decompresses the lumbar spine without removing bone or placing the spine at risk of destabilization.
MSK Specialty Procedure Library™Clinical Procedure Guide Standard v1.0GoHealthcare Practice Solutions
1. Evidence at a Glance
Source page 2
This one-page executive summary orients prior authorization, utilization management, revenue cycle, and clinical teams before the detailed sections that follow. Every entry is expanded and sourced later in this guide.
Domain Summary
Procedure Percutaneous placement of a titanium interspinous spacer (Superion) between adjacent
spinous processes to limit extension and indirectly decompress the neural elements. No bone is removed and no direct decompression is performed.
FDA status Superion Indirect Decompression System — premarket approval (PMA P140004), 2015.
It is the only FDA-approved stand-alone interspinous spacer currently marketed in the United States (X-STOP was withdrawn in 2015).
Medicare No National Coverage Determination and no active MAC Local Coverage
Determination. The prior First Coast LCD (L34006) and companion article were retired in April 2020; coverage is now adjudicated case-by-case on medical necessity aligned to the FDA-approved indication. In practice the procedure is widely reimbursed by Medicare when the FDA-indication criteria are documented.
Commercial Broadly experimental / investigational. Cigna (via eviCore), Aetna, UnitedHealthcare, coverage Humana, Molina, and most Blue Cross Blue Shield plans classify stand-alone interspinous
spacers as investigational for lumbar spinal stenosis. This is the inverse of many procedures and the central operational challenge of this guide.
Evidence level Two-year outcomes from a randomized FDA-IDE pivotal trial and durable five-year single-arm
data support the device; payers counter that the pivotal comparator was another interspinous spacer (X-STOP), not surgical decompression or conservative care, which limits comparative certainty.
Image guidance Required. Fluoroscopic guidance is used for placement; pre-procedure MRI or CT must
document moderate stenosis and the anatomy supporting candidacy.
Prior authorization Effectively mandatory. Commercial requests are frequently delegated to eviCore or Carelon
and often denied as investigational; Medicare Advantage applies plan-level utilization management.
Conservative At least 6 months of non-operative treatment is part of the FDA indication and a therapy near-universal documentation expectation.
Diagnostic block Not applicable. Candidacy is imaging- and symptom-driven (neurogenic claudication relieved
by flexion).
Key documentation Moderate stenosis on imaging; neurogenic intermittent claudication with relief in flexion; no
more than Grade 1 spondylolisthesis; failed 6 months conservative care; one or two contiguous lumbar levels; functional impairment.
Approval Best positioned as moderate LSS with neurogenic claudication in a patient who has failed considerations conservative care and is unsuitable for or wishes to avoid open decompression. Severe
stenosis, instability, and greater-than-Grade-1 spondylolisthesis undermine candidacy.
2. Overview
Source page 2
The Vertiflex Procedure places the Superion Indirect Decompression System (IDS), a titanium interspinous spacer, between the spinous processes of one or two adjacent lumbar levels. Delivered
percutaneously through a cannula and then deployed, the spacer acts as a
spacer-and-extension-blocker: it holds the interspinous space open and restricts painful lumbar extension, which enlarges the central canal and neural foramina in the standing and walking positions where symptoms occur. Because it works by limiting extension rather than by removing tissue, the mechanism is indirect decompression — the defining distinction from tissue-removing procedures.
This contrast matters operationally as much as clinically. The MILD procedure (Guide 01) physically debulks hypertrophied ligamentum flavum and removes a small portion of lamina — a direct decompression with no implant. The Vertiflex Procedure removes no bone and leaves a permanent titanium implant, which introduces device coding, MRI-conditionality considerations, and a very different payer-coverage profile. The Superion device was developed by Vertiflex, Inc. and has been part of the Boston Scientific pain portfolio since 2019.
3. Relevant Anatomy (High-Level)
Source page 3
Lumbar spinal stenosis is a narrowing of the central canal, lateral recesses, and/or neural foramina that compresses the cauda equina and exiting nerve roots. In the degenerative form most relevant to this procedure, narrowing is driven by a combination of ligamentum flavum hypertrophy, facet arthropathy, and disc bulging. Symptoms characteristically worsen with lumbar extension (standing, walking) and improve with flexion (sitting, leaning forward) — the physiologic basis for neurogenic claudication and for a device that works by blocking extension.
The interspinous space — the gap between adjacent spinous processes — is the implantation target. Adequate spinous-process bone quality and integrity are prerequisites, because the device transmits load to the spinous processes; osteoporosis or a prior fracture at the level compromises fixation. This guide intentionally limits anatomy to what drives candidacy, documentation, and coverage, and is not a procedural technique manual.
4. Clinical Indications
Source page 3
The Superion IDS carries a specific, narrow FDA-approved indication. Documentation that mirrors this language is the foundation of every successful authorization:
- Skeletally mature patients with neurogenic intermittent claudication — pain, numbness, and/or
cramping in the legs, buttocks, or groin.
- Secondary to a diagnosis of moderate degenerative lumbar spinal stenosis (not mild, not severe).
- With or without Grade 1 spondylolisthesis — greater-than-Grade-1 listhesis is outside the
indication.
- Radiographic evidence of thickened ligamentum flavum, narrowed lateral recess, and/or central
canal or foraminal narrowing on x-ray, MRI, and/or CT.
- Impaired physical function in patients who experience relief in flexion from leg/buttock/groin
symptoms, with or without back pain.
- Symptoms persisting after at least 6 months of non-operative treatment.
- Treatment at one or two contiguous lumbar levels.
The phrase ‘moderate’ stenosis is not decorative. Payers and reviewers use the mild/moderate/severe gradient to sort candidacy: mild stenosis undercuts medical necessity, and severe stenosis is generally directed toward direct decompression. The imaging narrative should state the severity explicitly.
5. Patient Selection
Source page 4
Appropriate selection is the single largest determinant of both clinical outcome and authorization success. The ideal candidate shows a clean alignment of symptoms, examination, and imaging:
- Neurogenic claudication with a clear positional pattern — worse in extension/standing/walking,
better in flexion/sitting.
- Moderate central and/or lateral recess stenosis on MRI or CT, at one or two contiguous levels.
- No more than Grade 1 (stable) spondylolisthesis and no dynamic instability on flexion-extension
imaging.
- Documented functional limitation (reduced walking tolerance, standing intolerance) with objective
measures where available.
- Failure of a genuine, dated course of conservative care over at least 6 months.
- A patient who is unsuitable for, or wishes to avoid, open decompression or general anesthesia --
frequently an older patient with comorbidity. Superion is best understood as a rung on the treatment ladder between injections and open surgery: for the patient who has exhausted conservative care but does not yet warrant — or cannot tolerate — laminectomy, it offers a reversible, bone-preserving option.
6. Contraindications
Source page 4
The following exclude candidacy or place the patient outside the FDA-approved indication; each is a frequent root cause of denial when overlooked:
- Greater-than-Grade-1 spondylolisthesis, or dynamic/segmental instability.
- Severe stenosis, or stenosis requiring direct decompression; cauda equina syndrome.
- Prior decompression (laminotomy/laminectomy) or fusion at the target level.
- Osteoporosis or otherwise compromised bone quality that jeopardizes spinous-process fixation; prior
spinous-process fracture.
- Significant scoliosis or fixed/ankylosed segment at the target level.
- Spinous process anatomy that cannot accommodate or securely retain the device.
- Active systemic infection or infection localized to the implantation site; known titanium allergy.
- Morbid obesity (historically BMI over 40 in Medicare LCD criteria) where it precludes safe placement.
7. Medical Necessity
Source page 4
For this procedure, medical necessity is won or lost on how precisely the record maps to the FDA-approved indication and to the payer's stated criteria. Because the commercial default posture is investigational, the record must do more than establish a diagnosis — it must pre-empt the most likely objection. A defensible medical-necessity statement establishes each of the following in the clinician's own words:
- Diagnosis with specificity: moderate degenerative lumbar spinal stenosis with neurogenic
claudication (ICD-10-CM M48.062), at the specific level(s) treated.
- Positional symptom pattern: symptoms worse in extension and relieved by flexion — the
physiologic rationale for an extension-blocking spacer.
- Imaging correlation: severity stated as moderate; ligamentum flavum, lateral recess, and/or
central/foraminal findings named; listhesis grade documented as no greater than Grade 1.
- Conservative-care failure: a single, dated timeline covering at least 6 months of physical therapy,
medication, and injection therapy with outcomes.
- Functional impairment: objective limitation (walking/standing tolerance) tied to the stenosis.
- Candidacy rationale: why indirect decompression is appropriate now and why open
decompression is being deferred or avoided.
8. Imaging Requirements
Source page 5
Imaging is the evidentiary backbone of the request. Recent MRI is preferred; CT or CT-myelogram is used when MRI is contraindicated. The report — or a clinician addendum quoting it — should state, at minimum:
- Stenosis severity graded explicitly as moderate at the treated level(s).
- The anatomic contributors: ligamentum flavum thickening, lateral recess narrowing, and/or central
canal or foraminal narrowing.
- Spondylolisthesis grade (must be no greater than Grade 1 to remain within the indication).
- Absence of findings that would redirect care — gross instability, severe stenosis, or a level better
served by direct decompression.
- Flexion-extension radiographs where instability is in question.
A recurring, avoidable denial arises when a multilevel MRI narrative never isolates the treated level or never states the severity. The measurement and the grade should appear in the request narrative, not merely in an attached film the reviewer may not open.
9. Conservative Treatment Requirements
Source page 5
At least 6 months of non-operative treatment is embedded in the FDA indication and is a near-universal payer expectation. The record should consolidate, on one dated timeline:
- A supervised physical therapy or activity-modification program, with dates and response.
- Pharmacologic management (analgesics, NSAIDs, neuropathic agents) with agents, duration, and
outcome.
- Interventional therapy where used — epidural steroid injections — with dates and degree/duration of
relief.
- A clear statement that symptoms and functional limitation persisted despite the above.
Scattered references to ‘failed conservative care’ across multiple notes are the single most common documentation gap. Consolidating them into one timeline routinely converts a pend into an approval.
10. CMS / Medicare Coverage
Source page 5
Medicare coverage of the Vertiflex Procedure is, in an important sense, the mirror image of MILD. There is no National Coverage Determination for interspinous spacers, and there is no active Medicare
Administrative Contractor Local Coverage Determination or article that governs them. First Coast Service Options previously maintained an LCD (L34006) and a companion article, but these were retired in April 2020, and no MAC replaced them.
In the absence of an NCD or LCD, coverage is adjudicated case-by-case under the general reasonable-and-necessary standard of Section 1862(a)(1)(A) of the Social Security Act, benchmarked to the FDA-approved indication. In practice, this makes the procedure widely reimbursable by traditional Medicare when the FDA-indication criteria are clearly documented — which is why the device is marketed as covered nationally. The operational caution is that ‘no LCD’ cuts both ways: there is no published criteria set to point to, so the burden of demonstrating medical necessity sits entirely on the clinical record.
- No NCD and no active MAC LCD/LCA specific to interspinous spacers — confirm current MAC articles
before relying on this.
- Adjudication is medical-necessity based and benchmarked to the FDA-approved indication for the
Superion IDS.
- Recognized settings: hospital outpatient (POS 22, TOB 13X/85X) and ambulatory surgery center
(POS 24).
- The procedure is device-intensive in the outpatient setting; the implant is reported with HCPCS
C1821 on facility claims.
- Medicare Advantage plans apply their own utilization management and may be more restrictive than
traditional Medicare; verify plan-specific rules.
Gohealthcare Prior Authorization Insight
For Medicare, the FDA indication is the coverage criteria With no LCD to cite, the FDA-approved indication becomes the de facto medical-necessity standard. Build the Medicare record to demonstrate each element — moderate stenosis, neurogenic claudication with relief in flexion, no more than Grade 1 spondylolisthesis, one or two levels, and failed 6-month conservative care. A record that tracks the indication line-by-line is the strongest protection against a post-payment audit.
11. Commercial Payer Comparison
Source page 6
The defining feature of the commercial landscape is uniformity in the wrong direction: despite FDA premarket approval and routine Medicare payment, the major national commercial payers broadly classify stand-alone interspinous spacers as experimental, investigational, or unproven for lumbar spinal stenosis. Utilization management is frequently delegated to eviCore or Carelon. Always verify the member's specific plan and the controlling policy version, because posture varies by product and updates are frequent.
Payer / vendor Typical posture (verify current policy)
Cigna (via eviCore) Interspinous process spacer/decompression devices, including Superion, considered
experimental/investigational/unproven for all indications (eviCore CMM-608).
Aetna Interspinous distraction/decompression devices considered experimental/investigational
for lumbar spinal stenosis.
UnitedHealthcare Stand-alone interspinous decompression devices not covered; 2026 policy addresses
interspinous devices largely in the fusion context.
Humana Interspinous process decompression spacers, including Superion, listed as not covered /
experimental-investigational.
Molina Interspinous decompression devices considered experimental/investigational for spinal
stenosis.
Blue Cross Blue Most plans classify stand-alone interspinous/interlaminar spacers as investigational for all Shield plans applications; criteria vary by plan.
Carelon Where delegated, applies interspinous-spacer criteria consistent with an investigational
posture; confirm the current guideline.
The reason cited across these policies is remarkably consistent: the pivotal randomized trial compared Superion to another interspinous spacer (X-STOP) rather than to surgical decompression or conservative care, and payers read the broader evidence base as insufficient to establish an improvement in net health outcome versus established alternatives. Understanding that specific objection is essential to writing a request or appeal that actually engages it.
12. Prior Authorization Workflow
Source page 7
Because coverage posture diverges so sharply between Medicare and commercial plans, the workflow must branch on benefit type at the very first step.
Step Action Owner
1. Verify benefits & Identify plan and UM vendor; determine whether the plan covers, PA / front posture covers-with-criteria, or excludes interspinous spacers as investigational. office
2. Branch on benefit Medicare/MA: build to the FDA indication. Commercial: anticipate an PA type investigational denial and plan the exception/appeal path early.
3. Confirm Moderate stenosis + neurogenic claudication with relief in flexion; no more Clinical indication than Grade 1 listhesis; one or two levels.
4. Assemble Imaging with severity and level; consolidated 6-month conservative-care PA + clinical evidence packet timeline; functional measures; medical-necessity statement.
5. Submit to correct Route to eviCore, Carelon, or the plan per delegation; use the current portal PA entity and policy version.
6. Track & respond Monitor status; answer clinical pends within the deadline; prepare for PA
peer-to-peer.
7. Authorization & Record the auth number, approved code(s)/level(s), and validity dates; PA / scheduling schedule with matching documentation. scheduling
8. Denial pathway For an investigational denial, pursue the plan's exception/medical-necessity PA / physician
appeal with a targeted rebuttal; escalate methodically.
13. Common Prior Authorization Denials
Source page 8
Denial reason Root cause Prevention
Investigational / Commercial policy excludes Confirm posture first; where excluded, pursue a
experimental stand-alone interspinous medical-necessity exception or appeal, not a routine
spacers regardless of request.documentation.
Severity mismatch Imaging reads as mild Document moderate stenosis explicitly at the treated
(undercuts necessity) or level(s).severe (redirected to direct decompression).
Spondylolisthesis Greater-than-Grade-1 listhesis Screen with flexion-extension imaging; select only stable, out of range or instability present. up-to-Grade-1 cases.
Insufficient Missing or undated therapy, Provide a single dated 6-month conservative-care timeline conservative care medication, or injection with outcomes.
history.
Level/anatomy More than two levels, prior Limit to one or two contiguous virgin levels with adequate issues surgery at the level, or poor bone.
spinous-process bone quality.
Coding mismatch 22867 (with open Use 22869/+22870 for stand-alone placement; include
decompression) used instead C1821 on facility claims.of 22869, or device code omitted on the facility claim.
14. Appeal Strategies
Source page 8
Appeals succeed when they engage the specific denial rationale. For this procedure that rationale is usually ‘investigational,’ which calls for a different response than a routine criteria gap.
- For investigational denials: engage the actual objection — acknowledge the comparator
limitation of the pivotal trial and argue medical necessity for this specific patient, citing FDA PMA status, two-year randomized data, and durable five-year outcomes; request the plan's medical-necessity exception where a categorical exclusion exists.
- For criteria denials: supply the missing element directly — the severity grade, the dated
conservative-care course, the listhesis grade — and map each to the plan's own criteria.
- Prepare peer-to-peer strategically: brief the treating physician with the severity, positional
symptom pattern, conservative-care timeline, and the exact policy language before the call.
- Escalate methodically: use the plan's internal levels, then external/independent review; for
Medicare Advantage, follow the CMS appeal timeline.
- Close the loop: feed every overturned denial back into the intake checklist so the same gap is not
repeated.
15. Coding & Billing Overview
Source page 8
This is an operational coding snapshot, not a full reimbursement methodology. The defining coding decision is distinguishing stand-alone spacer placement (Superion, no open decompression) from
spacer placement performed with open decompression (coflex), because they carry different code families.
Applicable CPT® codes
CPT® Operational description (paraphrased) Notes
22869 Insertion of an interlaminar/interspinous process stabilization/distraction Primary code for the
device, without open decompression or fusion, including image guidance Vertiflex/Superion
when performed, lumbar; single level. procedure.+22870 Same service, second level. Add-on to 22869; the
device treats one or two contiguous levels.
22867 Interlaminar/interspinous device WITH open decompression, lumbar; single Different procedure
level. (e.g., coflex). Do notuse for stand-alone Superion.
+22868 Same, second level (with open decompression). Add-on to 22867.
0171T / Prior Category III codes for spinous-process distraction device. Superseded by +0172T 22869/+22870
(Category I). Do not use.
HCPCS
- C1821 — interspinous process distraction device (implantable). Reported on
hospital-outpatient/ASC facility claims to capture the device in this device-intensive procedure. No separate professional device code applies.
Common ICD-10-CM diagnosis codes
ICD-10-CM Description Billing note
M48.062 Spinal stenosis, lumbar region, with neurogenic claudication. Primary supporting
diagnosis for candidacy.
M48.061 Spinal stenosis, lumbar region, without neurogenic claudication. Use when
claudication is not documented.
M48.07 Spinal stenosis, lumbosacral region. Use per documented
level.
M43.16 Spondylolisthesis, lumbar region. When Grade 1
spondylolisthesis co-exists; grade must be documented.
M48.06 Spinal stenosis, lumbar region (unspecified). NON-BILLABLE
parent — will be rejected. Requires 6th-character specificity (M48.061 / M48.062).
Modifiers, place of service, and ASC considerations
- Modifier 50: 22869 is reported per level with the add-on +22870 for the second level; follow payer
guidance rather than defaulting to bilateral modifiers.
- Modifier 52 (reduced services): may apply if the intended service is not completed; document
rationale.
- Place of service: 22 (hospital outpatient) or 24 (ambulatory surgery center); TOB 13X/85X for
facility claims.
- ASC: confirm the code is on the ASC-payable list for the payer and that the C1821 device and
device-intensive packaging are handled correctly.
- Documentation supporting code selection: level(s) treated, stand-alone placement without
open decompression, image guidance, and the specific device. CPT® is a registered trademark of the American Medical Association. Code descriptions here are paraphrased for operational use; consult the current CPT® code set and payer policy for official language.
16. Device Manufacturers & System Considerations
Source page 10
This is an implant-based procedure, so device facts are part of medical necessity, coding, and downstream imaging safety.
- Device: Superion Indirect Decompression System (IDS), a titanium-alloy interspinous spacer
delivered percutaneously through a cannula and deployed between the spinous processes.
- Manufacturer: developed by Vertiflex, Inc. (Carlsbad, CA); acquired by Boston Scientific
(definitive agreement May 9, 2019; acquisition closed June 11, 2019).
- Regulatory basis: FDA premarket approval (PMA P140004), 2015 — a higher evidentiary
pathway than 510(k) clearance, and a point worth surfacing in appeals.
- Market position: the only FDA-approved stand-alone interspinous spacer currently marketed in the
U.S.; the earlier X-STOP device was withdrawn in 2015.
- MRI conditionality: the Superion IDS is MR Conditional and may be scanned under defined
conditions at 1.5T and 3.0T. Because it is titanium, patients should disclose the implant before any MRI, and imaging teams should apply the manufacturer's current MRI conditions.
- Reversibility: the implant preserves bone and can be removed if conversion to open
decompression later becomes necessary — a genuine clinical and counseling advantage.
Gohealthcare Clinical Insight
Device facts are authorization facts On an implant procedure, the device details are not trivia — they are levers. PMA (not 510(k)) status, the two-year randomized and five-year durability data, and MR-Conditional labeling are exactly the points that a well-built medical-necessity letter or appeal should cite, and exactly the points a generic request omits.
17. Clinical Documentation Checklist
Source page 10
- ☐ Diagnosis of moderate degenerative lumbar spinal stenosis stated explicitly.
- ☐ Neurogenic claudication documented, with relief in flexion and worsening in extension.
- ☐ Level(s) treated identified (one or two contiguous lumbar levels).
- ☐ Spondylolisthesis grade documented as no greater than Grade 1; stability confirmed.
- ☐ Imaging (MRI/CT) with severity grade and anatomic contributors named.
- ☐ Consolidated 6-month conservative-care timeline with outcomes.
- ☐ Functional impairment (walking/standing tolerance) recorded.
- ☐ Medical-necessity statement mapping the record to the FDA indication.
- ☐ Correct coding recorded (22869 / +22870; C1821 on facility claim; M48.062).
- ☐ Benefit-type branch documented (Medicare vs. commercial pathway).
18. Procedure Comparison
Source page 11
Placing Vertiflex among adjacent options clarifies both candidacy and coding.
Procedure Mechanism Implant Primary Typical positioning
CPT®
Vertiflex / Indirect: interspinous Yes 22869 / Moderate LSS; avoid/defer open Superion spacer blocks extension (titanium) +22870 surgery
MILD / PILD Direct: debulk ligamentum No 62330 / Central LSS driven by ligamentum
flavum +62331 flavum hypertrophy coflex Interlaminar device WITH Yes 22867 / Stenosis treated with
open decompression +22868 decompression plus stabilization Laminectomy Direct open No 63047 family More severe/multilevel stenosis;
decompression definitive decompressionThe two operational traps live in this table: coding stand-alone Superion as 22867 (which implies open decompression), and conflating Vertiflex with MILD despite entirely different mechanisms, implants, codes, and coverage profiles.
19. GoHealthcare Clinical Insights
Source page 11
- Lead with the severity grade. ‘Moderate’ stenosis at the named level is the hinge of candidacy; a
request that never states it invites a severity denial.
- Name the positional pattern. ‘Relief in flexion’ is FDA-indication language and the physiologic
rationale for the device — put it in the narrative.
- Consolidate conservative care into one dated timeline; scattered mentions read as an unmet
requirement.
- Confirm and document stability. A single line ruling out greater-than-Grade-1 listhesis pre-empts a
common objection.
- Put the device facts in the letter — PMA status, randomized and durable outcomes, MR-Conditional
labeling.
20. GoHealthcare Leadership Perspective
Source page 11
The Vertiflex Procedure is the clearest case in the minimally invasive spine portfolio of a coverage paradox: an FDA premarket-approved device that traditional Medicare generally reimburses but that most commercial plans classify as investigational. For an operations leader, the strategic response is
not to treat every plan the same. It is to branch the workflow on benefit type at intake, to build the Medicare record to the FDA indication as the de facto criteria set, and to enter commercial cases with clear eyes — knowing when a case warrants an exception appeal and when the realistic path is a redirect to a covered alternative. Disciplined benefit verification and honest posture-setting at the front end protect both the patient's timeline and the practice's clean-claim rate, and they keep the organization out of the twin failure modes of futile submissions and post-payment exposure.
21. GoHealthcare Prior Authorization Insight
Source page 12
Gohealthcare Prior Authorization Insight
Verify posture before you promise a date The most expensive mistake on this procedure is scheduling a commercial patient before confirming coverage posture. Because the national commercial default is investigational, an intake that assumes coverage produces cancellations, patient frustration, and write-offs. The GoHealthcare standard is a benefit-and-posture check at step one: covered, covered-with-criteria, or excluded. For Medicare, gate the record to the FDA indication; for commercial, decide early between an exception appeal and a redirect. That single upfront branch prevents the majority of avoidable denials and rescheduling on this device.
22. GoHealthcare Case Study
Source page 12
Clinical scenario A 71-year-old with progressive neurogenic claudication reports standing and walking tolerance reduced to a few minutes, relieved by sitting or leaning forward. MRI shows moderate central and lateral recess stenosis at L3-L4 and L4-L5 with ligamentum flavum thickening and Grade 1, stable spondylolisthesis. The patient has completed physical therapy, a trial of neuropathic medication, and two epidural steroid injections with only transient relief, and wishes to avoid open decompression given age and comorbidity.
Documentation challenges The MRI narrative labeled findings ‘multilevel degenerative change’ without stating severity as moderate, and the conservative-care history was spread across several notes without a consolidated timeline. The commercial plan's policy classified interspinous spacers as investigational.
Prior authorization barriers The commercial request was denied as experimental/investigational per the delegated UM vendor. The Medicare secondary pathway was viable, but the record did not yet map cleanly to the FDA indication.
Payer considerations & workflow The team obtained a radiology addendum stating moderate severity at the treated levels, assembled a single dated 6-month conservative-care timeline, documented Grade 1 stability on flexion-extension imaging, and rewrote the medical-necessity statement to track the FDA indication element by element. For the commercial denial, they filed a medical-necessity exception citing PMA status and the randomized and durable outcome data and engaging the comparator objection directly.
Resolution & outcome
The primary Medicare pathway approved on the strength of the indication-aligned record; the procedure was performed in the ASC (POS 24) and coded 22869 with +22870 for the second level, with C1821 on the facility claim. The patient reported improved standing and walking tolerance at follow-up.
Lessons learned
- Severity language was the hinge — ‘moderate’ had to be stated, not implied.
- Branching on benefit type early prevented wasted cycles on the commercial exclusion.
- Mapping the record to the FDA indication served as the de facto Medicare criteria set.
- Correct coding (22869 / +22870 with C1821, not 22867) kept the clean claim clean.
23. GoHealthcare Best Practices
Source page 13
- Branch the workflow on benefit type (Medicare vs. commercial) at intake, before scheduling.
- Template the medical-necessity narrative around the FDA indication so severity, positional relief,
listhesis grade, and conservative care are always present.
- State the stenosis severity grade in the request narrative, not only in the attached imaging.
- Screen stability with flexion-extension imaging and document a listhesis grade of no greater than
Grade 1.
- Map 22869 / +22870 and device code C1821 in the EHR and charge master; suppress 22867
auto-suggestions for stand-alone cases.
- Maintain a payer matrix of coverage posture and delegation (eviCore / Carelon) by plan and product.
- Feed every overturned denial back into the intake checklist.
24. Common Mistakes
Source page 13
- Scheduling a commercial patient before confirming coverage posture on a broadly investigational
procedure.
- Coding stand-alone Superion as 22867 (which implies open decompression) instead of 22869.
- Omitting the C1821 device code on the facility claim for a device-intensive procedure.
- Submitting M48.06 (non-billable parent) instead of M48.061 / M48.062.
- Failing to state stenosis severity as moderate, inviting a severity denial.
- Missing greater-than-Grade-1 listhesis or instability during selection.
- Treating an investigational exclusion as if it were a routine criteria gap (and vice versa).
25. Pearls and Pitfalls
Source page 13
Pearls & Pitfalls
High-yield reminders Pearl: Build the record to the FDA indication — on Medicare it is effectively the coverage criteria set. Pearl: ‘Moderate stenosis, relief in flexion, up to Grade 1 listhesis’ is the three-part phrase that anchors candidacy; say all three. Pitfall: Assuming commercial coverage because the device is FDA-approved and Medicare pays — most commercial plans exclude it as investigational. Pitfall: Coding stand-alone Superion as 22867, or dropping C1821 on the facility claim. Pitfall: Confusing Vertiflex (indirect, implant, 22869) with MILD (direct, no implant, 62330) — different mechanism, coverage, and codes.
26. Frequently Asked Questions
Source page 14
Q1. What CPT® code is used for the Vertiflex Procedure? 22869 for a single lumbar level and add-on +22870 for a second level — the codes for interspinous spacer placement without open decompression. Q2. How is Vertiflex different from coflex in coding? Superion is placed without open decompression (22869/+22870). coflex is placed with open decompression (22867/+22868). Using the wrong pair misrepresents the procedure. Q3. What is the device code? HCPCS C1821 (interspinous process distraction device, implantable), reported on facility claims for this device-intensive procedure. Q4. Is Vertiflex the same as MILD? No. MILD is a direct decompression that debulks ligamentum flavum with no implant (62330/+62331). Vertiflex places a permanent titanium spacer and works by indirect decompression (22869/+22870). Q5. What is the FDA status of Superion? Premarket approval (PMA P140004), granted in 2015 — a higher evidentiary pathway than 510(k) clearance. Q6. Does Medicare cover the Vertiflex Procedure? There is no NCD and no active MAC LCD; traditional Medicare adjudicates on medical necessity aligned to the FDA indication and generally reimburses well-documented cases. Verify current MAC articles. Q7. Why do commercial plans deny it?
Most national commercial payers classify stand-alone interspinous spacers as
experimental/investigational, largely because the pivotal trial compared Superion to another spacer rather than to surgical decompression or conservative care. Q8. Which payers consider it investigational? Cigna (via eviCore), Aetna, UnitedHealthcare, Humana, Molina, and most BCBS plans, at the time of writing. Always confirm the current policy version. Q9. What stenosis severity is required? Moderate degenerative lumbar spinal stenosis. Mild stenosis undercuts necessity; severe stenosis is generally directed to direct decompression.
Q10. Is spondylolisthesis allowed? Grade 1 spondylolisthesis is within the indication; greater-than-Grade-1 listhesis or instability is not. Q11. How many levels can be treated? One or two contiguous lumbar levels. Q12. How much conservative care is expected? At least 6 months of non-operative treatment, documented on a single dated timeline. Q13. What imaging is needed? MRI (or CT/CT-myelogram) documenting moderate stenosis, the anatomic contributors, and the listhesis grade at the treated level(s). Q14. What is the primary diagnosis code? M48.062 — lumbar spinal stenosis with neurogenic claudication. M48.06 is a non-billable parent and will be rejected. Q15. Is the implant MRI compatible? The Superion IDS is MR Conditional and may be scanned under defined conditions at 1.5T and 3.0T; patients should disclose the implant before any MRI. Q16. Can the device be removed later? Yes. The spacer preserves bone and can be removed if conversion to open decompression becomes necessary. Q17. Where is it performed? Hospital outpatient (POS 22) or ambulatory surgery center (POS 24); it is commonly performed in the ASC. Q18. Is a diagnostic block required? No. Candidacy is imaging- and symptom-driven, based on moderate stenosis and neurogenic claudication with relief in flexion. Q19. What is the strongest single predictor of approval? A record that maps element-by-element to the FDA indication — severity, positional relief, listhesis grade, levels, and failed conservative care. Q20. How should an investigational denial be appealed? Engage the objection directly: cite PMA status and the randomized and durable outcome data, acknowledge the comparator limitation, and request the plan's medical-necessity exception. Q21. Who manufactures Superion? It was developed by Vertiflex, Inc. and has been part of Boston Scientific since 2019. Q22. What is the biggest coding trap? Reporting stand-alone Superion as 22867 (with open decompression) or omitting the C1821 device code on the facility claim.
27. Key Takeaways
Source page 15
- Vertiflex places the Superion interspinous spacer for indirect decompression of moderate LSS — no
bone removed, permanent titanium implant.
- Coding: 22869 / +22870 (without open decompression) plus device C1821; do not use 22867 (with
open decompression).
- FDA PMA (2015) — the only marketed stand-alone interspinous spacer in the U.S.
- Medicare: no NCD, no active LCD; adjudicated on medical necessity to the FDA indication and
generally reimbursed.
- Commercial: broadly investigational — branch the workflow on benefit type and plan the appeal
path early.
- Primary diagnosis M48.062; document moderate severity, relief in flexion, and up-to-Grade-1
stability.
28. Future Outlook
Source page 16
The central variable for this procedure is not clinical adoption but commercial coverage. Continued accumulation of longer-term and comparative-effectiveness evidence — particularly head-to-head data against direct decompression and conservative care — is the lever most likely to move commercial policies off an investigational posture. Professional-society coverage recommendations continue to evolve, and utilization-management vendors periodically revise their guidelines. Practices should re-verify eviCore, Carelon, and major commercial policies each cycle, and watch for any new MAC articles addressing interspinous spacers, since the current absence of an LCD could change. The operational posture — branch on benefit type, build to the FDA indication, appeal with the specific evidence — remains stable regardless of how coverage shifts.
29. References
Source page 16
- U.S. Food & Drug Administration. Superion Interspinous Spacer — Premarket Approval (PMA) P140004.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm
- American Medical Association. CPT® code set (22869, +22870; 22867, +22868).
https://www.ama-assn.org/practice-management/cpt
- Patel VV, Whang PG, Haley TR, et al. Superion interspinous process spacer for intermittent neurogenic
claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial. Spine (Phila Pa 1976). 2015;40(5):275-282. PMID 25494323.
- Patel VV, Nunley PD, Whang PG, et al. Superion InterSpinous Spacer for moderate degenerative lumbar spinal
stenosis: durable three-year results of a randomized controlled trial. J Pain Res. 2015;8:657-662. PMID 26491369. https://pmc.ncbi.nlm.nih.gov/articles/PMC4634825/
- Nunley PD, Patel VV, Orndorff DG, et al. Five-year durability of stand-alone interspinous process decompression
for lumbar spinal stenosis. Clin Interv Aging. 2017;12:1409-1417. PMID 28919727. https://pmc.ncbi.nlm.nih.gov/articles/PMC5590777/
- Nunley PD, Patel VV, Orndorff DG, et al. Superion Interspinous Spacer treatment of moderate spinal stenosis:
4-year results. World Neurosurg. 2017;104:279-283. PMID 28479526.
- Boston Scientific Corporation. Completion of acquisition of Vertiflex, Inc. (Form 8-K, June 11, 2019).
https://www.sec.gov/Archives/edgar/data/885725/000088572519000032/vertiflexclosingpressrelea.htm
- Boston Scientific. Superion Indirect Decompression System — indications and MRI conditionality.
https://www.bostonscientific.com/en-US/medical-specialties/pain-management/mri-conditionality.html
- eviCore healthcare. Musculoskeletal / lumbar decompression clinical guidelines (CMM-608).
https://www.evicore.com/provider/clinical-guidelines
- North American Spine Society. Coverage recommendations: interspinous devices. https://www.spine.org
- ICD-10-CM 2026: M48.061 / M48.062 (lumbar spinal stenosis); M43.16 (lumbar spondylolisthesis).
https://www.cms.gov/medicare/coding-billing/icd-10-codes
30. Reading Recommendations
Source page 17
- FDA PMA P140004 approval documents — the authoritative indication and labeling for Superion.
- Patel 2015 (Spine) pivotal RCT and Nunley 2017 five-year durability — the core evidence cited in
appeals.
- eviCore CMM-608 and your top commercial plans' current interspinous-spacer policies — the
controlling coverage language.
- NASS coverage recommendations for interspinous devices — society context for medical-necessity
arguments.
31. Related GoHealthcare Resources (Internal Links)
Source page 17
- GoHealthcare MSK Specialty Procedure Library — Guide 01: MILD / PILD (direct decompression
contrast).
- GoHealthcare MSK Specialty Procedure Library — Interspinous Spacer Procedures (category
overview: Superion vs. coflex).
- GoHealthcare Prior Authorization Playbook — investigational-denial appeal templates.
- GoHealthcare Revenue Cycle Knowledge Center — device-intensive procedure and ASC packaging
guidance.
32. Recommended Downloads
Source page 17
- Vertiflex/Superion coding quick-card (22869 / +22870; device C1821; M48.062).
- FDA-indication-aligned medical-necessity template for interspinous spacer requests.
- Benefit-type branching checklist (Medicare vs. commercial) for intake.
- Investigational-denial appeal letter template with PMA and outcome citations.
33. Visual Recommendations
Source page 17
- High-level anatomy illustration: interspinous space and extension-blocking mechanism of indirect
decompression.
- Decision tree: candidacy by stenosis severity, listhesis grade, and level count.
- Benefit-type branching flowchart (Medicare indication pathway vs. commercial exception pathway).
- Coverage matrix: Superion posture by major payer and UM vendor.
- Coding comparison table: 22869/+22870 vs. 22867/+22868 vs. 62330/+62331.
34. Document History
Source page 17
Version Date Summary
1.0 2026 Initial publication under GoHealthcare Clinical Procedure Guide Standard v1.0. Reflects
CPT® 22869/+22870 and device code C1821, FDA PMA P140004 status, the absence of an active Medicare LCD, and the current commercial-payer investigational landscape.
35. Educational Disclaimer
Source page 18
This document is part of the GoHealthcare Practice Solutions Knowledge Center and is intended for educational and operational reference purposes only. It is not a physician training manual, procedural technique guide, clinical textbook, or legal advice, and it does not replace physician clinical judgment, payer policy review, or official CMS guidance. It is not a substitute for specialty society procedural training. Coverage policies, coding guidance, and reimbursement requirements change frequently and vary by payer, product, plan, and jurisdiction; they must always be verified against the applicable payer policy and current regulatory sources before clinical or billing decisions are made. CPT® is a registered trademark of the American Medical Association. Product and company names, including Vertiflex® and Superion®, are the property of their respective owners and are referenced for identification only.
Developed by Pinky Maniri
Founder & Chief Executive Officer, GoHealthcare Practice Solutions
National Musculoskeletal Specialty Management Services Organization (MSO)